Orion Pharma: Company Profile

Background

Overview

Orion Pharma is a globally operating Finnish pharmaceutical company, established in 1917, dedicated to building well-being through the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. With a century-long legacy, Orion Pharma has become a significant player in the pharmaceutical industry, offering a diverse portfolio of proprietary and generic medicines and consumer health products.

Mission and Vision

Orion Pharma's mission is to build well-being by providing effective drugs and therapies that help patients manage their illnesses and improve their quality of life. The company's vision is to become a truly global, innovative, and patient-focused pharmaceutical company by the 2030s, serving societies and transforming patients' lives worldwide.

Primary Area of Focus

The company's pharmaceutical research and development (R&D) primarily focus on oncology and pain management, aiming to deliver innovative treatments in these critical therapeutic areas.

Industry Significance

Orion Pharma holds a significant position in the pharmaceutical industry, with its products available in over one hundred countries. The company's commitment to quality and innovation has established it as a trusted provider of essential medicines and health solutions globally.

Key Strategic Focus

Core Objectives

• Innovation in R&D: Continuously developing new drugs and treatment methods, with a strong emphasis on oncology and pain management.

• Global Expansion: Expanding market presence by entering new regions and strengthening existing markets.

• Sustainability and Ethics: Upholding high standards of sustainability and ethical practices in all operations.

Specific Areas of Specialization

• Oncology: Developing treatments for various types of cancer.

• Pain Management: Creating therapies for acute and chronic pain conditions.

Key Technologies Utilized

• Active Pharmaceutical Ingredients (APIs): Manufacturing APIs to ensure control over the quality and supply of essential components.

• Advanced Manufacturing Facilities: Utilizing state-of-the-art facilities to produce a wide range of dosage forms, including tablets, capsules, syrups, and injectables.

Primary Markets Targeted

• Europe: Strengthening presence in existing markets and exploring new opportunities.

• Asia: Expanding footprint, particularly in countries like India and China.

• Global: Ensuring product availability in over one hundred countries.

Financials and Funding

Funding History

Orion Pharma is a publicly listed company on the Helsinki Stock Exchange, with its A and B shares traded under the ticker symbol ORNBV. The company has a history of raising capital through public offerings to support its expansion and R&D initiatives.

Total Funds Raised

Specific figures regarding total funds raised are not publicly disclosed.

Recent Funding Rounds

Details of recent funding rounds are not publicly available.

Notable Investors

As a publicly traded company, Orion Pharma's investors include institutional investors, mutual funds, and individual shareholders.

Intended Utilization of Capital

Capital raised is primarily utilized for:

• Research and Development: Investing in innovative drug development, particularly in oncology and pain management.

• Global Expansion: Enhancing market presence in existing and new regions.

• Manufacturing Facilities: Upgrading and expanding manufacturing capabilities to meet global demand.

Pipeline Development

Key Pipeline Candidates

• ODM-212: A drug in development for the treatment of malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE).

Stages of Clinical Trials or Product Development

• Phase 2 Trials: ODM-212 is undergoing Phase 2 trials for MPM and EHE.

Target Conditions

• Malignant Pleural Mesothelioma (MPM): A rare and aggressive cancer affecting the lining of the lungs.

• Epithelioid Hemangioendothelioma (EHE): A rare vascular tumor that can affect various organs.

Relevant Timelines for Anticipated Milestones

• Initiation of Phase 2 Trials: January 2026.

• Expected Completion of Phase 2 Trials: Not specified; timelines depend on trial outcomes and regulatory processes.

Technological Platform and Innovation

Proprietary Technologies

• Easyhaler®: A dry powder inhaler device for respiratory treatments.

Significant Scientific Methods

• Advanced Drug Delivery Systems: Utilizing innovative technologies to enhance the efficacy and patient compliance of treatments.

• Biologics Development: Engaging in the development of biologic therapies, including monoclonal antibodies.

Leadership Team

Key Executive Profiles

• Liisa Hurme: President and CEO.

• Professional Background: Extensive experience in the global pharmaceutical industry.

• Key Contributions: Led Orion Pharma through significant growth and innovation, recognized as Leader of the Year 2026 by the Helsinki Region Chamber of Commerce.

• Mikael Silvennoinen: Chairman of the Board.

• Professional Background: Background in business management and corporate governance.

• Key Contributions: Provides strategic direction and oversight to Orion Pharma's operations.

Leadership Changes

• Farzana Khan: Appointed Independent Director in 2025.

• Predecessor: Not specified.

• Date of Appointment: 2025.

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The global pharmaceutical market is substantial, with significant growth potential driven by aging populations, increasing healthcare access, and advancements in medical research.

• Industry Trends: A shift towards personalized medicine, increased focus on biologics, and the rise of digital health technologies.

Competitor Analysis

• Huvepharma: A global pharmaceutical company specializing in animal health and human pharmaceuticals.

• Shimadzu Corporation: A Japanese company providing instruments and equipment for pharmaceutical research and manufacturing.

• STADA Arzneimittel AG: A German pharmaceutical company focusing on generic and over-the-counter products.

• Ipsen: A global biopharmaceutical group focusing on oncology, neuroscience, and rare diseases.

Strategic Collaborations and Partnerships

• Bayer: Collaboration for the co-development and commercialization of Nubeqa® (darolutamide), a treatment for prostate cancer.

• Abzena: Exclusive commercial license agreement for Abzena’s antibody, enhancing Orion Pharma's oncology pipeline.

Operational Insights

• Strategic Considerations: Orion Pharma's focus on oncology and pain management positions it in competitive therapeutic areas, necessitating continuous innovation and strategic partnerships to maintain and enhance market position.

• Competitive Advantages: Strong R&D capabilities, a diversified product portfolio, and a global sales network.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Innovation: Continuing to invest in R&D to develop novel therapies, particularly in oncology and pain management.

• Global Expansion: Strengthening presence in existing markets and entering new regions to broaden the customer base.

• Sustainability: Implementing sustainable practices across operations to meet environmental and social responsibilities.

Future Business Directions

• Biologics and Biosimilars: Expanding into biologics and biosimilars to diversify the product portfolio.

• Digital Health: Integrating digital health solutions to enhance patient engagement and treatment outcomes.

Opportunities for Expansion

• Emerging Markets: Targeting emerging markets with growing healthcare needs and improving access to medicines.

• Strategic Partnerships: Forming alliances to co-develop and commercialize new therapies, leveraging complementary strengths.

Contact Information

• Official Website: Orion Pharma

• Social Media Profiles:

• LinkedIn: Orion Pharma LinkedIn